Literature DB >> 12471021

Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation.

Regina Fluhrer1, Gerd Multhaup, Andrea Schlicksupp, Masayasu Okochi, Masatoshi Takeda, Sven Lammich, Michael Willem, Gil Westmeyer, Wolfram Bode, Jochen Walter, Christian Haass.   

Abstract

The beta-amyloid precursor protein (beta APP) is proteolytically processed by two secretase activities to produce the pathogenic amyloid beta-peptide (A beta). N-terminal cleavage is mediated by beta-secretase (BACE) whereas C-terminal intramembraneous cleavage is exerted by the presenilin (PS) gamma-secretase complex. The A beta-generating gamma-secretase cleavage principally occurs after amino acid 40 or 42 and results in secretion of A beta-(1-40) or A beta-(1-42). Upon overexpression of BACE in cultured cells we unexpectedly noticed a reduction of secreted A beta-(1-40/42). However, mass spectrometry revealed a truncated A beta species, which terminates at amino acid 34 (A beta-(1-34)) suggesting an alternative gamma-secretase cut. Indeed, expression of a loss-of-function variant of PS1 inhibited not only the production of A beta-(1-40) and A beta-(1-42) but also that of A beta-(1-34). However, expression levels of BACE correlate with the amount of A beta-(1-34), and A beta-(1-34) is produced at the expense of A beta-(1-40) and A beta-(1-42). Since this suggested that BACE is involved in a C-terminal truncation of A beta, we incubated purified BACE with A beta-(1-40) in vitro. Under these conditions A beta-(1-34) was generated. Moreover, when conditioned media containing Abeta-(1-40) and A beta-(1-42) were incubated with cells expressing a loss-of-function PS1 variant together with BACE, A beta-(1-34) was efficiently produced in vivo. These data demonstrate that an apparently gamma-secretase-dependent A beta derivative is produced after the generation of the non-truncated A beta via an additional and unexpected activity of BACE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12471021     DOI: 10.1074/jbc.M211485200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

2.  Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid deposits.

Authors:  Yasushi Tomidokoro; Agueda Rostagno; Thomas A Neubert; Yun Lu; G William Rebeck; Blas Frangione; Steven M Greenberg; Jorge Ghiso
Journal:  Am J Pathol       Date:  2010-03-12       Impact factor: 4.307

3.  beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice.

Authors:  Michael Willem; Ilse Dewachter; Neil Smyth; Tom Van Dooren; Peter Borghgraef; Christian Haass; Fred Van Leuven
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

Review 4.  Proteolytic degradation of amyloid β-protein.

Authors:  Takaomi Saido; Malcolm A Leissring
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

Review 5.  Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis.

Authors:  Gaurav Pandey; Vibin Ramakrishnan
Journal:  Biophys Rev       Date:  2020-09-15

Review 6.  Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Authors:  Julie Dunys; Audrey Valverde; Frédéric Checler
Journal:  J Biol Chem       Date:  2018-08-24       Impact factor: 5.157

7.  A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease.

Authors:  Erik Portelius; Robert A Dean; Mikael K Gustavsson; Ulf Andreasson; Henrik Zetterberg; Eric Siemers; Kaj Blennow
Journal:  Alzheimers Res Ther       Date:  2010-03-29       Impact factor: 6.982

8.  Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence.

Authors:  Ayano Kimura; Saori Hata; Toshiharu Suzuki
Journal:  J Biol Chem       Date:  2016-09-29       Impact factor: 5.157

9.  Twenty Years of Presenilins--Important Proteins in Health and Disease.

Authors:  Jochen Walter
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

10.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.